Intech Medical to Acquire 23.18% Stake in Valgen Holding Corporation for RMB 738 Million to Expand Structural Heart Portfolio

Gelonghui May 12 | INT Medical announced that the company plans to acquire approximately 23.18% of a target company's equity for a total consideration of about RMB 738 million. The transaction was formalized through share transfer agreements signed with the sellers on May 11 and 12, 2026. The target company is an exempted company incorporated under the laws of the Cayman Islands, holding 100% equity of Valgen Medtech, which focuses on the research, development, production, and sales of interventional technologies and products for atrioventricular valve diseases. This acquisition aims to enrich INT Medical’s product portfolio in the structural heart disease sector and enhance its competitiveness and long-term development potential in the cardiovascular intervention field.